| |
|
|
|
Xtalks, online
2023 -7-10
This webinar will consider the current state of science in Alzheimer’s research, including what is known currently and what is on the horizon as more than 1,000 new people face a diagnosis each day. Attendees will hear from the Global Alzheimer’s Platform Foundation (GAP), whose inaugural study, Bio-Hermes, evaluated the ability of several promising blood-based and digital biomarkers to reflect brain amyloid PET scans in participants enrolled at clinical trial sites to determine if there is a relationship between the technologies used and identifying key hall markers of Alzheimer’s disease, enrolling an unprecedented number of people from racial and ethnic minority populations. All the data cannot be helpful without the critical eye of optimized data analysis, and Pentara Corporation will discuss the importance of quality data and how the Bio-Hermes data looks to stand up in this competitive environment.
Join the featured speakers as they review the findings from the Bio-Hermes study and talk about what this means for Alzheimer’s research at large.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Jeffrey Cummings, Director, Chambers-Grundy Center for Transformative Neuroscience, UNLV Dr. Richard Mohs, Chief Scientific Officer, Global Alzheimer’s Platform Foundation Dr. Suzanne Hendrix, CEO, Pentara Corporation John Dwyer, President and CEO, Global Alzheimer’s Platform Foundation
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -7-10
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|